Skip to main content

Table 1 Baseline demographics and clinical characteristics of the ITT population

From: Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer

Characteristic Cisplatin + gemcitabine + axitinib
(n = 38)
Age, years  
 Mean (SD) 60.5 (7.1)
 Median (range) 59.5 (47–73)
Gender  
 Male 34 (89.5)
 Female 4 (10.5)
Race  
 White 37 (97.4)
 Black 1 (2.6)
Smoking status  
 Smoker 33 (86.8)
 Non-smoker 5 (13.2)
Tumour histology  
 Squamous cell carcinoma 38 (100)
Disease stage  
 IIIB 5 (13.2)
 IV 33 (86.8)
ECOG performance status  
 0 12 (31.6)
 1 26 (68.4)
Prior surgery 17 (44.7)
 Bronchoscopy 11 (28.9)
 Lymph node/pleural biopsy 6 (15.8)
 Lobectomy 2 (5.2)
 Thoracic wall resection 1 (2.6)
  1. Values are n (%) unless otherwise noted. ECOG, Eastern Cooperative Oncology Group; ITT, intent-to-treat; SD, standard deviation.